Copyright © 2018 UCSD ADRC.
All rights reserved.


Clinical Trials

Clinical Trial Registry

Are you interested in clinical trials but don't currently see one that suits you? You can now join our ADRC Registry to be placed on a list for future studies. 

Participants can be normal controls, have a slight memory problem, or be diagnosed with early to moderate AD. 

*Call the ADRC 858-822-4800 and ask for Christina Gigliotti, Ph.D. for more information.

Clinical Trials Currently Enrolling New Participants

A4 Trial: Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease

The purpose of the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the "A4 study" for short) is to test whether a new investigational treatment, called an amyloid antibody, can slow memory loss caused by Alzheimer’s disease. Amyloid is a protein normally produced in the brain that can build up in older people, forming amyloid plaque deposits. Scientists believe this buildup of deposits may play a key role in the eventual development of Alzheimer’s disease-related memory loss. The overall goal of the A4 study is to test whether decreasing amyloid with antibody investigational treatment can help slow the memory loss associated with amyloid buildup in some people. 

The A4 study invites older individuals (ages 65-85) who have normal thinking and memory function but who may be at risk for memory loss due to Alzheimer’s disease, but have no outward signs of the disease to participate in the study. We seek to enroll 1,000 adults who have an “elevated” level of amyloid plaque in their brain. Physicians and researchers will use an imaging test called a PET scan to determine whether a potential participant has evidence of this plaque buildup. People who do not show evidence of elevated amyloid in their brains will not be able to participate, but may be asked to participate in a separate study. This group will not receive the investigational drug or placebo (i.e., an inactive substance designed to mimic the appearance of a drug), but will complete the same memory tests every six months to compare changes in cognition over time.

The A4 study lasts for three years, and participants will be required to visit the clinical research site once a month. Participants will be assigned at random to receive either the investigational drug or a placebo and will be monitored over the course of the three years. All clinical studies, including the A4 study, may involve some risks associated with participation. If you are considering participating in A4, you will have detailed discussions with physicians and research staff regarding the investigational treatment and other aspects of the A4 study. 

To watch the A4 study video click here: